Genome Analysis Services

Gene expression analysis studies the way genes are transcribed to synthesize functional gene (RNA species or protein) products, e.g., tumor antigens. Gene profiling compares RNA expression levels in multiple genes while gene screening compares multiple samples. In both cases, analyzing your RNA targets requires precise and accurate target-specific data.

Charles River performs genome analysis using NanoString nCounter™ technology. The method is robust, highly-reproducible, and faster than RNAseq and microarrays, detecting the gene expression of up to 800 genes in a single reaction, with high sensitivity and linearity across a broad range of expression levels. Able to simultaneously analyze DNA, RNA, and protein in a single sample, the method requires no enzymatic manipulation, e.g., reverse transcription or cDNA library preparation/amplification, reducing bias.

Assessing immune modulation at the preclinical, in vivo pharmacology and first-in-human clinical trial stages of drug discovery in a contract research organization

Assessing Immune Modulation at the Preclinical, In Vivo Pharmacology and First-in-Human Clinical Trial Stages of Drug Discovery

Traditionally, primary and secondary endpoints in first-in-human clinical trials are concerned with safety. Expanding the remit of these studies to include exploratory biomarkers provides early information on efficacy and can confirm mode of action of the therapeutic in humans.
Download the Poster

Applying Genomic Analysis in Drug Development

Gene expression profiling of patient-derived samples can provide actionable data to support your drug discovery program. We have developed optimized in vitro assays in disease-relevant pharmacology models, to assess potential therapeutic candidates.

  • Clinical PD biomarker identification in LPS-stimulated whole blood: Genome expression profiling can identify potential biomarkers, e.g., for the assessment of a new anti-inflammatory therapeutic. In a proof-of-concept assay, we treated whole blood with LPS and LPS and dexamethasone as the standard of care. The resulting changes from the gene expression profiling allowed us to identify and select potential biomarkers suitable for more focused downstream analysis with qPCR and Luminex®.
  • Transcription profiling in atopic dermatitis and psoriasis skin biopsies: Charles River’s genome analysis services provide a tool for tracking changes from gene expression profiling of various tissue types, including challenging tissues like skin. This approach is validated by measuring differential gene expression in samples from healthy, atopic dermatitis and psoriasis donors using a custom gene panel of ~200 genes known to be involved in these disease processes.
  • Autoimmune gene expression profiling in a model of multiple sclerosis: Our autoimmune genome analysis uses RNA isolated from spinal cord samples from an experimental model of multiple sclerosis. Our Autoimmunity Profiling Gene Panel elucidates the effect of novel therapeutics on immune responses by determining molecular mechanisms and identifying potential biomarkers alongside efficacy monitoring.
  • Tumor-infiltrating lymphocyte (TIL) or tumor gene expression analysis: Our tumor infiltrating assay uses RNA isolated from snap-frozen tumor sections to analyze differential gene expression. The assay uses defined gene panel that targets aspects of innate/adaptive immunity or tumor gene expression. This platform provides an insight into the type and quality of the immune response generated.
  • Alternative transcription profiling techniques: Our team can also perform qPCR on selected genes panels and potential biomarkers and RNAseq analysis when programs require.

Talk to an Expert


Frequently Asked Questions (FAQs) about Genome Analysis